Clinical trial
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating…
NCT00267722 · Facet Biotech, Industry · Completed
Key facts
| NCT number | NCT00267722 |
|---|---|
| Title | Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease |
| Official title | A Phase 2a, Open-label Study of Visilizumab in Patients With Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn's Disease |
| Lead sponsor | Facet Biotech, Industry |
| Collaborators | PDL BioPharma, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | Visilizumab |
| Enrollment | 18 |
| Start date | Feb 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Dec 21, 2005 |
| Last update posted | Mar 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: